Pharma: Page 8
-
Real Chemistry’s CEO on biopharma’s outlook in 2024
Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.
By Michael Gibney • Dec. 7, 2023 -
4 historic FDA approvals from 2023
This year’s many firsts included a vaccine for RSV and a drug that slows Alzheimer’s disease.
By Alexandra Pecci • Dec. 6, 2023 -
Trendline
Clinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
The digital therapeutics revolution is here. Will payers play ball?
Apps, VR and more could play an increasingly vital role in the wider goals of creating value-based treatments — if the industry can get payers to sign on.
By Kelly Bilodeau • Dec. 5, 2023 -
The weight loss market looks unstoppable. How high could it go?
Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.
By Kelly Bilodeau • Dec. 4, 2023 -
The fortunes and flops of pharma M&A
Hindsight offers a better perspective on why some deals are fruitful and others fail.
By Alexandra Pecci • Dec. 4, 2023 -
3 standout digital innovations in pharma this year
IDEA Pharma just released its Digital Innovation Index. Here are the top companies they identified and some of the standout advances the industry made.
By Meagan Parrish • Dec. 1, 2023 -
Deep Dive
Pharma benefited from basing business overseas. An international tax effort could spur a rethink.
U.S. tax law changes six years ago slashed large pharma companies' rates and saved them billions. Now, a push for an international floor could disrupt their R&D accounting.
By Jonathan Gardner • Nov. 29, 2023 -
Octave Bioscience is navigating the Parkinson’s labyrinth with Michael J. Fox’s help
A grant from the notorious Parkinson’s foundation has sped up Octave’s timeline to further advance biomarker development in the field.
By Kelly Bilodeau • Nov. 29, 2023 -
Q&A
The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.
By Michael Gibney • Nov. 28, 2023 -
Biopharma’s top 5 IPOs of 2023 (so far)
Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.
By Alexandra Pecci • Nov. 28, 2023 -
How EMD Serono plans to hit its lofty goals in R&D
The company’s global heads of oncology R&D reveal how strategic partnerships are key to its launch plans following layoffs in the U.S.
By Alexandra Pecci • Nov. 27, 2023 -
As alcohol-related deaths climb, new drugs could curb the urge to drink
A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.
By Kelly Bilodeau • Nov. 27, 2023 -
The biopharma COO’s playbook
Connie Chang, COO at ONL Therapeutics, describes what it takes to bring a CEO’s vision to life.
By Alexandra Pecci • Nov. 21, 2023 -
Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs
Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.
By Kelly Bilodeau • Nov. 20, 2023 -
A startling drop in U.S. life expectancy — and how pharma could help turn the tide
The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.
By Meagan Parrish • Nov. 17, 2023 -
Q&A
AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
By Michael Gibney • Nov. 16, 2023 -
The power of genomics-based healthcare remains largely untapped
23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.
By Alexandra Pecci • Nov. 15, 2023 -
6 ways to improve clinical trial diversity — as shown by J&J
Johnson & Johnson Innovative Medicine’s director of diversity, equity and inclusion in clinical trials shares key strategies for making DEI work.
By Alexandra Pecci • Nov. 14, 2023 -
Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.
The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.
By Kelly Bilodeau • Nov. 13, 2023 -
Sponsored by ClinicalMind
Optimizing KOL engagement and technology utilization in 2024
What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?
Nov. 13, 2023 -
5 of the best paid biopharma CEOs
As revenue growth remained high last year, so did biopharma CEO pay in the U.S.
By Alexandra Pecci • Nov. 10, 2023 -
How pharma leaders talk about ethics in a highly criticized industry
The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?
By Michael Gibney • Nov. 9, 2023 -
An at-home flu vaccine? If approved, it could open the door to more DIY options
A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.
By Kelly Bilodeau • Nov. 8, 2023 -
The obesity drug effect: What medical device executives are saying
Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.
By Susan Kelly • Nov. 6, 2023 -
Opinion
The thorniest questions facing pharma, according to a leading bioethicist
Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.
By Michael Gibney • Nov. 6, 2023